Gossamer Bio, Inc.(GOSS)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Gossamer Bio, Inc. (GOSS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores GOSS at 8.2/100 on a 32-signal composite quality model, placing it at rank #2,933 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include institutional flow (0.9) and balance sheet strength (1.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 8.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Gossamer Bio, Inc. reports quarterly revenue of $9.2M, net income of $16.9M, free cash flow of $-39.4M. Top institutional holders of GOSS by reported 13-F value include TANG CAPITAL MANAGEMENT, D. E. Shaw, 683 Capital Management, based on the most recent SEC filings. GOSS trades on the Nasdaq exchange and files with the SEC under CIK 1728117. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GOSS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Gossamer Bio, Inc. directly from SEC EDGAR.